LU LUPIN
Lupin Q1 2026
LULUPIN

Lupin Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 6 Aug 2025

Management summary

  • Lupin reported a strong Q1 FY26 with double-digit revenue growth and significant EBITDA margin expansion to 26.6%.
  • Robust US performance, including the successful launch of Tolvaptan, and solid growth in India and Other Developed Markets..
  • The company continues to invest heavily in R&D, particularly in complex and specialty products, and is addressing regulatory observations at its Pithampur sites.
  • While facing some headwinds from LOE in India and generic competition in the US, management remains optimistic about future growth from its pipeline and strategic initiatives.

Source: Inve concall analysis and management guidance record.

Highlights

  • Sales for Q1 FY26 came in at INR 6,164 crores, a growth of 11.8% YoY.

  • EBITDA margin expanded by 330 basis points YoY to 26.6%.

  • US business recorded sales of USD 282 million, its highest since Q4 FY2017.

  • Successful launch of Tolvaptan with sole first-to-file exclusivity.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue4,208 4,486 5,709
EBITDA1,411 1,746 2,730
Net profit985 1,291 2,128
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Profitability

  • EBITDA margin Profitability · fiscal year · High confidence 24% to 25%

R&D

  • R&D spend as % of sales R&D · FY26 · High confidence 7.5% to 8.5%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Tolvaptan contribution and overall top-line growth outlook Direct
So top-line growth for the year, as we have guided earlier, we expect strong double-digit, both for the company and for the U.S. We launched Tolvaptan in late May. So, it was partial quarter.

Clarifies the partial contribution of Tolvaptan in Q1 and reiterates strong double-digit growth guidance for the full year.

Asked by Kunal Dhamesha

India business growth and drag from adjacency businesses Direct
It's primarily the tender business, it's the institution business, which has impacted. And as we've discussed before, that's lumpy. But by and large, I think we're in a good place on the Global Institution Business as well. ... So, the impact on our EBITDA would be close to about

Explains the reasons for lower India growth (lumpy tender business) and quantifies the EBITDA drag from new, loss-making adjacency businesses.

Asked by Kunal Dhamesha

Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 11 risks, concerns & management red flags
  • 5 watchlist triggers for Q2 FY26
  • +14 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image